– USA, MA – STRM.BIO, a pre-clinical biotechnology company that is leveraging extracellular vesicles (EVs) to deliver gene therapies and develop new therapeutics for rare blood diseases, today announced the appointment of Dr. Dawn Bell (PharmD) to its Board as an Independent Director
About Dr. Dawn Bell
Dr. Dawn Bell has been starting and scaling life science businesses ranging from academic spinouts to leading pharmaceutical companies for the past 20 years. Most recently, she was at Novartis and held leadership roles in global drug development, medical affairs, and portfolio strategy.
While at Novartis, Dr. Bell delivered the approval of Entresto ($4B) 18 months ahead of schedule as global GM, securing FDA Break-Through and Fast-Track status. As VP, Clinical Development and Medical Affairs and member of the Executive Team for Novartis Canada, she led the launch preparation for eight medicines across five therapeutic areas in four years, including building the teams that launched the first two gene therapies approved in Canada (Zolgensma and Luxturna). Prior to Novartis, Dr. Bell was the founding CEO of an Emory University spinout where she raised a seed round of venture capital. Prior to that she was GM of a commercial-stage rare disease company where she led BD&L and successfully out-licensing of the lead product and was an early commercial leader at The Medicines Company contributing to market cap growth from $400M to $2B within three years. Dr. Bell earned her PharmD from the University of Florida.
About STRM.BIO
Based in Boston, MA, STRM.BIO is a pre-clinical, VC-backed biotechnology company that is leveraging extracellular vesicles (EVs) to deliver gene therapy in a better way: simpler, safer, practical. Our work will open the door to the future of medicine for patients living with rare diseases worldwide. STRM.BIO is committed to bringing gene therapy to life.
For more information: https://strm.bio/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.